Company Overview
Snapshot
Founded in May 2012 by Rafi Herzog, AlphaMet operates with 1–10 employees. The company has raised $820,000 across three funding rounds from one investor. In February 2020, AlphaMet secured funding from PipelBiz.
Business overview
AlphaMet, formerly CyclaPlex, develops, manufactures, and markets medical devices within the Health Tech & Life Sciences sector. Its core product, the CyclaPlex Correction System, is an implant device designed to prevent bone osteotomy, shorten recovery time, and reduce pain for patients undergoing bunion surgery. The company serves the medical treatment and therapeutics market, specifically targeting surgeons and healthcare providers in the orthopedic field.
Strategic signal
In February 2017, AlphaMet announced its plans to expand the global reach of its bunion treatment solutions. This signals a strategic intent to broaden market penetration and establish the company's orthopedic system as a worldwide standard, indicating potential for international growth and increased market share in the medical device industry.
Log in to access full profile ›Company Intelligence Q&A
- When was AlphaMet founded?
- AlphaMet was founded in May 2012 by Rafi Herzog.
- What is AlphaMet's primary product?
- AlphaMet's primary product is the CyclaPlex Correction System, an implant device designed for bunion surgery to prevent bone osteotomy, shorten recovery time, and reduce pain.
- What was a significant development for AlphaMet in February 2017?
- In February 2017, AlphaMet announced its intention to treat bunions worldwide, indicating a strategic focus on global market expansion for its medical device.
- Has AlphaMet received any funding?
- AlphaMet has raised a total of $820,000 across three funding rounds. In February 2020, the company secured funding from PipelBiz.
- What is the regulatory status of the CyclaPlex Correction System?
- The CyclaPlex Correction System is FDA cleared for use by surgeons.